Silk Road Medical Inc is a medical device company focused on improving the treatment of neurovascular diseases, particularly through minimally invasive procedures
The company's flagship product is designed to enhance the treatment of carotid artery disease, which can lead to stroke. By developing innovative technologies that facilitate less invasive options for patients and healthcare providers, Silk Road Medical aims to enhance clinical outcomes and improve the overall patient experience in neurovascular care. Their commitment to advancing medical technology positions them as a key player in the healthcare industry, striving to address critical needs in vascular health.
The top 10 positions in QQQ constitute almost half of its total weight. Although current tech leaders may have become too pricey two Invesco Nasdaq ETFs target future tech leaders: QQQJ and QQQS. Both have
Boston Scientific Co (NYSEBSX) is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs.
NEW YORK, Aug. 24, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silk Road Medical, Inc. (NasdaqGS: SILK) to Boston Scientific Corporation (NYSEBSX). Under the terms of the proposed transaction, shareholders of Silk Road will receive $27.50 in cash for each share of Silk Road that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2024.
Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, June 29, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Boston Scientific Corporation (NYSEBSX), a global leader in medical device technology, announced to acquire Silk Road Medical, Inc. NASDAQ: SILKNASDAQSILK)
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silk Road Medical, Inc. (NasdaqGS: SILK) to Boston Scientific Corporation (NYSEBSX). Under the terms of the proposed transaction, shareholders of Silk Road will receive $27.50 in cash for each share of Silk Road that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR system, a breakthrough in stroke prevention. Transaction closes in H2 2024.
